SGLT2 Is Tied to Fewer Post-MI Deaths in T2D Mitchel L. Zoler, PhD

https://www.medscape.com/viewarticle/997097?src= AMSTERDAM — Adults with type 2 diabetes who were on a sodium-glucose cotransporter 2 (SGLT2) inhibitor at the time of a type 1 (acute atherothrombotic) myocardial infarction (MI) had a significant 36% lower rate of all-cause death compared with adults with type 2 diabetes and a similar MI who were not on an agent from this class during the year following the index MI, new observational data show.